The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49

Recent evidence has investigated the cost-effectiveness of magnetic resonance imaging in younger women with a BRCA1 mutation. This evidence has not been contrasted with existing cost-effectiveness standards to determine whether screening is appropriate, given limited societal resources

Richard P. A. Norman; D. Gareth Evans; Douglas F. Easton; Kenneth C. Young

2007

Scholarcy highlights

  • Recent evidence has investigated the cost-effectiveness of magnetic resonance imaging in younger women with a BRCA1 mutation. This evidence has not been contrasted with existing cost-effectiveness standards to determine whether screening is appropriate, given limited societal resources
  • The key benefit of MRI is that increased sensitivity leads to early detection, and improved prognosis
  • Probabilistic sensitivity analysis supported the cost-effectiveness of the parallel approach of mammography and MRI
  • It is necessary to extend this analysis beyond BRCA1 carriers within this age group, and to other age groups

Need more features? Save interactive summary cards to your Scholarcy Library.